Eli Lilly pushed next-generation weight-loss into sharper focus as phase 3 data for retatrutide (TRIUMPH-2) showed dose-dependent, large-scale weight loss in people with obesity and type 2 diabetes over 80 weeks, with meaningful cardiometabolic improvements alongside reductions in obesity by BMI thresholds. Separately, Novo Nordisk moved to strengthen its obesity bench with a preclinical once-weekly oral GLP-1R/GIPR dual agonist licensed from China’s Hengrui Pharma for $300 million upfront, with total deal value reaching $2.6 billion if development and commercial milestones are met. The asset is positioned to compete on convenience and tolerability against established injectable GLP-1 therapies. The parallel news underscores how metabolic competition is shifting from incremental efficacy toward outcomes that can translate into broader, more sustainable long-term use—particularly as payers and patients press for adherence-friendly regimens.